Pelthos Therapeutics Inc. — Form 8-K
Filed November 12, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 78/100
What the filing says
Pelthos announced Q3 2026 net product revenue of $15.2M (up 114% from $7.1M in Q3 2025), with 12,384 Zelsuvmi units dispensed and formulary coverage reaching 127M commercially covered lives. On October 30, 2026, Pelthos entered a definitive merger agreement with Castle Creek Biosciences (late-stage gene therapy company with lead candidate D-Fi for dystrophic epidermolysis bullosa), expected to close by end of Q1 2027. Pelthos also drew an additional $10.0M from Horizon Technology Finance (on top of $30M previously drawn), bringing total debt to $40M under a $50M facility, with $10M more available if trailing twelve-month revenue reaches $70M by December 2027.
Why this rating
Castle Creek merger is transformative for $6.7M market-cap company, adding gene therapy platform. Zelsuvmi strong revenue growth and debt financing substantial relative to size, but merger execution risk and negative stockholders' equity ($6.2M deficit) are concerns.
Tradability signal
NO TRADE
No trade: positive news with only +0.0% moved so far — good news prices in within seconds and long-side continuation has shown no measured edge (this cell: -0.33% over 4 hrs, n=451). (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
at our read · unknown $9.39 | +10 min · unknown $9.27 ▼ 1.33% | +30 min · unknown $9.01 ▼ 4.10% | +1 hr · unknown $9.23 ▼ 1.65% | +4 hrs · unknown $8.13 ▼ 13.37% |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 12, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.